CN100352915C - Bacillus subtilis, composite preparation, and method for preparing the composite preparation - Google Patents
Bacillus subtilis, composite preparation, and method for preparing the composite preparation Download PDFInfo
- Publication number
- CN100352915C CN100352915C CNB2005100454433A CN200510045443A CN100352915C CN 100352915 C CN100352915 C CN 100352915C CN B2005100454433 A CNB2005100454433 A CN B2005100454433A CN 200510045443 A CN200510045443 A CN 200510045443A CN 100352915 C CN100352915 C CN 100352915C
- Authority
- CN
- China
- Prior art keywords
- preparation
- bacillus subtilis
- phage
- compound formulation
- subtilis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a bacillus subtilis, a composite preparation thereof and a preparation method of the composite preparation. The bacillus subtilis is named bacillus subtilis LY-35, and conserved at the Common Microbe Culture Collection Center of the China Committee of Culture Collection for Microorganisms with the conservation number of CGMCC No. 1222. The preparation is a compound of the viable bacterium culture of the bacillus subtilis with bacteriophages of pathogenic bacteria, such as staphylococci, streptococcus, colibacillus, bacillus proteus, pseudomonas, salmonella, shigella, pasteurella, klebsiella, etc. The preparation can prevent and treat various diseases caused by conditional pathogenic bacteria, and can be a safe substitute or mixed microbial preparation of antibiotics, with no medicine residue, no pollution and high curative effect.
Description
Technical field
The present invention relates to a kind of subtilis and utilize the compound formulation of this strain preparation, and the preparation method of this compound formulation.
Background technology
In recent years, along with the development of China's aquaculture, the raising of intensification degree, bacteriosis has become the obstacle that the restriction aquaculture further develops.Particularly the suppuration inflammatory disease that is caused by a large amount of conditioned pathogens that exist in the environment such as staphylococcus, suis, intestinal bacteria, Bacillus proteus, pseudomonas, Salmonellas, shigella, pasteurellosis bacillus and Cray Bai Shi bacillus is widely current.Because the management and the abuse of antibiotics of the science of shortage have not only destroyed the microecological balance of normal microflora, and have produced a large amount of endurance strains, cause clinical therapeutic efficacy limited, cause the meat products quality to reduce, edible safety descends.Particularly children poultry in age is often come to an end to die of illness.Left drug in the meat product and Resistant strain can be passed to the mankind by food chain, and human beings'health is caused great threat.
Statistics according to China its feeding aspect: the piglet below 30 kilograms, the average originating rate of intestinal tract disease are 46.5%, and mortality ratio is 10.3%.Family's disease case fatality rate of causing of avian escherichia coli is 55.4%, the various bacteriosis of 4-12 week poultry easy infection in age particularly, and mortality ratio is sometimes up to 70%-80%; The mammitis of cow sickness rate accounts for 70% of whole cows, and endometritis sickness rate 20-30% accounts for 68.34% of infertility.
Abroad, according to the annual report statistics that bureau of animal husbandry of the Russian Federation provides, piglet chylopoietic disease morbidity is 75%, and wherein 20% is maldigestion, and 26-35% is a gastro-enteritis, and it is low that 6-8% shows as liver function, and 1.5% is peritonitis and other diseases.The case fatality rate of the bacillary gastrointestinal tract disease of piglet is 40-50%.
Use antibiotic practice in the world and show, adopt to be used alternatingly microbiotic and chemicals, or even the microbiotic of latest generation do not reach due effect usually yet, make worse off on the contrary.Because a large amount of staphylococcus, suis, intestinal bacteria, Bacillus proteus, pseudomonas, Salmonellas, shigella, pasteurellosis bacillus and Cray Bai Shi bacillus that exist have had very strong antibiotic resistance in plant.
According to patent CN1177637A, we know that subtilis Bacillus subtilis BS-3 is to E.Coli O
157Have antagonism, the preparation of composition can be treated maldigestion, acute and chronic enteritis and flora imbalance diarrhoea based on this.The viable bacteria amount is 5 * 10
8The time piglet use effect on the three fine.But its weak point is that Salmonella D enteriditis, Staphylococcus aureus, StreptococcusPyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsillapneumoniae are not had antagonistic action, Bacillus subtilis BS-3 does not have antibiotics resistant yet, thereby whether said preparation can use simultaneously with microbiotic and require study.
Summary of the invention
Technical problem to be solved by this invention is to create a kind of new subtilis and probiotics thereof.Preparation can either use jointly with microbiotic and chemicals, reduce the side effect of microbiotic and chemicals, the disease that endurance strain is caused has better therapeutic effect simultaneously, and uses this preparation also can prevent the diffusion of pathogenic bacterium, improves the natural immunity of livestock and poultry.
In order to address the above problem, the present invention has adopted following technical scheme.
A kind of subtilis, name is called Bacillus subtilis LY-35, and in China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation, its deposit number is: CGMCC NO.1222.
Utilize first kind of compound formulation of above-mentioned subtilis preparation, to have the Bacillus subtilis LY-35 and the E.Coli of representative configuration, cultivation, biochemical characteristic, the phage of Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae is a basic ingredient, the preparation compound formulation.Preparation contains:
1), the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2), the phage titer of one milliliter of compound formulation E.Coli, SalmonellaD, enteriditi, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, Klebsilla pneumoniae is 10
6(ten times of serial dilution methods);
3), enzyme suppresses stablizer: the EDTA of amount of formulation 0.5% (ethylenediamine tetraacetic acid (EDTA)).
Utilize second kind of compound formulation of above-mentioned subtilis preparation, to have the Bacillus subtilis LY-35 and the E.Coli of representative configuration, cultivation, biochemical characteristic, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabili,, the phage of ProteusVulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae is a basic ingredient, the preparation compound formulation.Preparation contains:
1), the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2), one milliliter of compound formulation E.Coli, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaemginosa, the phage titer of Klebsilla pneumoniae are 10
6(ten times of serial dilution methods).
3), antibiotic stablizer: the oxine vitriol of amount of formulation 1%.
Utilize the third compound formulation of above-mentioned subtilis preparation, to have the Bacillus subtilis LY-35 and the E.Coli of representative configuration, cultivation, biochemical characteristic, the phage of Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae is a basic ingredient, the preparation compound formulation.Preparation contains:
1), the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2), one milliliter of compound formulation E.Coli, Salmonella D enteriditis, StaphYlococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, the phage titer of Klebsilla pneumoniae are 10
6(ten times of serial dilution methods).
3), antibiotic stablizer and enzyme suppress stabilizing agent dosage: the oxine vitriol of amount of formulation 1% and 0.5% EDTA (ethylenediamine tetraacetic acid (EDTA)).
Utilize the 4th kind of compound formulation of above-mentioned subtilis preparation, to have the Bacillus subtilis LY-35 and the E.Coli of representative configuration, cultivation, biochemical characteristic, the phage of Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae is a basic ingredient, the preparation compound formulation.Preparation contains:
1), the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2), one milliliter of compound formulation E.Coli, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, the phage titer of Klebsilla pneumoniae are 10
6(ten times of serial dilution methods).
3), no stablizer and enzyme inhibitors
The preparation method of described subtilis compound formulation is:
1) preparation of Bacillus subtilis LY-35:
Use contains the synthetic medium cultivation Bacillussubtilis LY-35 of peptone, glucose, inorganic salt and trace element; On the synthetic agar substratum that contain peptone, glucose, inorganic salt and trace element of Bacillus subtilis LY-35 inoculation in the Tissue Culture Flask, place 37 ℃ thermostat container, cultivated 18-24 hour, then, lawn is washed from the agar surface upper punch, be inoculated in the seeding tank that contains same medium; Fermentation culture 3-4 hour, reach logarithmic phase, fermented product is inoculated into as seed in the fermentor tank of 100 liters, 250 liters or 500 liters, fermentation culture 18-20 hour, when becoming gemma, ends culture; Gains are concentrated to (100-120) * 10
9The CFU/ milliliter; Remove substratum, the sterilization sodium chloride solution with 0.9% replaces it; The make a living mixture of secular viable cell and gemma of enriched material, carry out Performance Detection after, use during for the preparation compound formulation.
2) preparation of phage:
Utilize liquid nutrient medium, regularly phage is cultivated in control in the bacterium that is in the logarithmic growth breeding, according to the different sorts of bacterium, be the substratum of basal component as culturing bacterium with Ma Shi meat soup, Huo Jingeshi meat soup, ordinary broth or with fermentation blood hydrolyzate; Each phage single culture, but the culture condition of all bacteriums is identical, and concentration is reached 5 * 10
7The bacteria suspension of CFU/ milliliter is added in the substratum, is to cultivate 1.0-1.5 hour under 37 ℃ of oxygen dissolveds condition that is 30-70% in temperature, makes its concentration reach (2-5) * 10
8The CFU/ milliliter is that the phage of l/30 adds then with infective dose, continues under the same conditions to cultivate 1-2 hour, up to the cracking fully of bacterium quilt; After fermentation culture, adopt tangential flow micro-filtration and ultrafiltration to remove the bacterium metabolite in the phage preparation and the protein of substratum; Use the aperture to carry out micro-filtration as the filter membrane of 0.2um, the film that uses filter to be limited to 150-200 KD carries out ultrafiltration; The phagocytolysis thing of different bacteriophages is mixed, after the stirring, carry out last degerming micro-filtration, the mixture that resulting compound phage composition is the phage of various conditioned pathogens; After carrying out Performance Detection, use during as the preparation compound formulation.
3) under aseptic condition, various compositions are combined, make compound formulation, can.
Subtilis has antagonistic action to most of pathogenic bacterium and conditioned pathogen, can stimulate body's immunity, improves the resistibility of body, and cultivates easily, and is strong to the adaptability of environment, is easy to preserve.So subtilis is one of desirable strain for preparing at present probiotics.
Phage is the virus that a class can kill bacteria, and is harmless to humans and animals, and in the age before microbiotic is found, phage is one of main preparation for the treatment of bacteriosis.
The present invention contains staphylococcus, intestinal bacteria, Bacillus proteus, pseudomonas, Salmonellas, shigella, pasteurellosis bacillus and the Cray Bai Shi bacillus of Bacillus subtilis LY-35 bacterial strain and differential high efficient by use the compound formulation of phage realizes treating the purpose of bacteriosis.
It compares the preparation of preparation of the present invention and patent CN1177637A and has following advantage:
1, Bacillus subtilis LY-35 not only has antagonism to E.Coli, and Salmonella Denteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae are also had very high antagonism.
2, the microbiotic and the Streptomycin sulphate of Bacillus subtilis LY-35 penicillin resistant series.
3, Bacillus subtilis LY-35 can improve conditioned pathogen to antibiotic susceptibility.
4, the main component phage of compound formulation has very high lytic activity for E.Coli, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae.
Compound formulation also has the following advantages:
1, safety has no side effect, and this preparation microorganism used therefor is all the beneficial microorganism that is present in the home, and people and animals are had no side effect.
2, by subtilis the natural antagonistic action of pathogenic bacteria and phage are killed the cracking of pathogenic bacteria and reached the purpose of eliminating pathogenic bacteria, alternative microbiotic or use with microbiotic reduces drug residue, improves the security of food such as meat milk.
3, Bacillus subtilis LY-35 penicillin resistant series and Streptomycin sulphate, thereby can be shared with above-mentioned microbiotic.
4, Bacillus subtilisLY-35 bacterial strain can reduce the resistance of pathogenic bacteria, shortens the course of treatment.
The microorganism of using
The microorganism that this preparation uses has two kinds, a kind of is subtilis (Bacillus subtilis), strain number is Bacillus subtilis LY-35, now is preserved in China Committee for Culture Collection of Microorganisms common micro-organisms center, is numbered CGMCC NO.1222; Another kind of microorganism is the phage at various pathogenic bacterias, and all phages are separated from the living environment of livestock and poultry by method in common, also use under this environment later on.
Bacillus subtilis LY-35 strain characteristics
1, cultivation, morphological specificity
Bacillus utilizes agar to cultivate through diel, and the cell size is (2-3) * 0.6um, and single, paired or bunchiness is arranged.Cell movement forms aerobic oval terminal spore, and when forming gemma, cell does not expand, and Gram dyeing is positive, and does not have pod membrane.Bacterium colony is canescence in meat peptone agar, tiny wrinkle is arranged, the wave edge, and thickness embeds agar gently.In broth culture, through 37 ℃, 18-24 hour cultivation forms little white mycoderm and bottom settlings, causes the substratum muddiness.
2, physiological characteristic
Aerobic, optimal growth condition: 37 ℃, PH 7.0-7.5
3, biochemical characteristic
Strain fermentation glucose, sucrose, maltose, N.F,USP MANNITOL form acid, and aerogenesis does not reduce lactose.Do not form indoles, hydrogen sulfide.The V-P reaction is positive, makes catalase, proteolytic enzyme, gelatinase, Ntn hydrolase does not form the ovum esterase, lipase, urase, do not form hemolysin and Tryptase, microbiotic (benzylpenicillin, the carboxy benzyl penicillin of bacterial strain penicillin resistant series, penbritin), polymyxin, peace Qu Nan, but to woods enzyme element, enzyme element, tsiklomitsin are insensitive through the ages.
4, the cultural method of bacterial strain
Common meat peptone substratum well-grown
5, antagonism
Bacterial strain is to the E.Coli of different serotypes, Salmonella D enteriditis, Staphylococcusaureus, Streptococcus pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, Klebsiella Pneumoniae has antagonism.
Antibiotics resistant and the antagonism of bacterial strain Bacillus Subtilis LY-35
Table one: the antibiotics resistant of bacterial strain Bacillus subtilis LY-35
| Test number (TN) | Antibiotics resistant (disk method of inspection) suppresses growth scope mm | |||
| Polymyxin | Rifomycin | Penicillin | Streptomycin sulphate | |
| 10 | 10 | 0 | 0 | 10±2 |
These data show: new bacterial strain is that very high antibiotics resistant is arranged
Table two: the antagonism of bacterial strain Bacillus subtilis LY-35
| Test number (TN) | Detect bacterium | Suppress growth scope mm |
| 10 | E.Coli | 25±2 |
| 10 | Salmonella D enteriditis | 20±2 |
| 10 | Staphylococcus aureus | 28±2 |
| 10 | Streptococcus Pyogenes | 20±2 |
| 10 | Proteus mirabilis | 20±2 |
| 10 | Proteus Vulgaris | 20±2 |
| 10 | Pseudomonas aeruginosa | 10±1 |
| 10 | Klebsiella Pneumoniae | 17±2 |
These data show that bacterial strain Bacillus subtilis LY-35 has very high antagonism to conditioned pathogen
Table three: antibiotic preparation is to the variation (mg/ml) of the minimum inhibitory concentration generation of some conditioned pathogen under the antagonistic action of Bacillus subtilis LY-35
This table proves that fully conditioned pathogen to the susceptibility of widely used antibiotic preparation in the medical treatment variation has taken place, and these variations are stable, have inheritance.
6, the security of bacterial strain Bacillus subtilis LY-35
According to the experiment regulation of China's true tumor preparation, detected the acute and chronic toxin of bacterial strain Bacillussubtilis LY-35 by current method.After carrying out acute and chronic toxin determination, visual inspection the test white mouse active situation, internal organ and the central nervous system of white mouse of having utilized microscopy is even used the maximum dosage that tolerates also not find because of the detoxifying function of bacterial strain Bacillus subtilis LY-35 pathological change to take place.After per os injects preparation, in the root of the tongue and stomach, do not find any reaction.Preparation is injected the abdominal cavity, find indivedual white mouse at the spleen film, slight inflammation symptom is arranged in liver film and spleen, liver, the perinephric cell tissue, after the week, above symptom alleviates greatly.Like this, it is as safe as a house just can to draw bacterial strain Bacillus subtilisLY-35, because it does not produce toxic side effect to internal organ and the tissue of experiment white mouse.
The characteristic of phage
Phage is the virus that a class can kill bacteria, and is harmless to humans and animals, and in the age before microbiotic is found, phage is one of main preparation for the treatment of bacteriosis.The used phage of this preparation is to separate from the living environment of livestock and poultry by method in common, also uses under this environment later on.
1, the working concentration of phage (tiring)
Phage stoste is by ten times of serial dilution methods, and it is 10 that mensuration is tired
6-10
7The time, E.Coli to different serotypes, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsilla pneumoniae bacterium all has activity.Determine that phage tiring in preparation is 10
6-10
7
2, the security of phage
Remove the metabolite of bacterial cell and the protein in the substratum in process of production, proteinic degree of purification reaches 98 ± 1.1%.Calculate the human dosimetry according to per weight, white mouse is enlarged 3500 times with dosage, in the oral cavity is injected into the white mouse body.According to experimental result, white mouse does not have death.Body weight does not descend, and internal organ do not have pathological change.In addition, the phage composition (going out according to the weight) of therapeutic dose is injected into intraperitoneal, does not also find toxicity (chronic toxicity) afterwards in 21 days.
The production of preparation
The various compositions of compound formulation are produced separately.
Use contains the synthetic medium cultivation Bacillussubtilis LY-35 of peptone, glucose, inorganic salt and trace element.On the synthetic agar substratum that contain peptone, glucose, inorganic salt and trace element of Bacillus subtilis LY-35 inoculation in the Tissue Culture Flask, place 37 ℃ thermostat container, cultivated 18-24 hour, then, lawn is washed from the agar surface upper punch, be inoculated in the seeding tank that contains same medium.Fermentation culture 3-4 hour, reach logarithmic phase, fermented product is inoculated into as seed in 100,250 or 500 liters the fermentor tank, fermentation culture 18-20 hour, when becoming gemma, ends culture.Gains are concentrated to (100-120) * 10
9The CFU/ milliliter.Remove substratum, the sterilization sodium chloride solution with 0.9% replaces it.The make a living mixture of secular viable cell and gemma of enriched material, carry out Performance Detection after, use during for the preparation compound formulation.Utilize liquid nutrient medium, regularly phage is cultivated in control in the bacterium that is in the logarithmic growth breeding, according to the different sorts of bacterium, be the substratum of basal component as culturing bacterium with Ma Shi meat soup, Huo Jingeshi meat soup, ordinary broth or with fermentation blood hydrolyzate.
Each phage single culture, but the culture condition of all bacteriums is identical, and concentration is reached 5 * 10
7The bacteria suspension of CFU/ milliliter is added in the substratum, is to cultivate 1.0-1.5 hour under 37 ℃ of oxygen dissolveds condition that is 30-70% in temperature, makes its concentration reach (2-5) * 10
8The CFU/ milliliter is that 1/30 phage adds then with infective dose, continues under the same conditions to cultivate 1-2 hour, up to the cracking fully of bacterium quilt.
For avoiding untoward reaction and removing toxin, after fermentation culture, adopt tangential flow micro-filtration and ultrafiltration to remove the bacterium metabolite in the phage preparation and the protein of substratum.Use the aperture to carry out micro-filtration as the filter membrane of 0.2um, the film that uses filter to be limited to 150 200 KD carries out ultrafiltration.The phagocytolysis thing of different bacteriophages is mixed, after the stirring, carry out last degerming micro-filtration, the mixture that resulting compound phage composition is the phage of various conditioned pathogens.After carrying out Performance Detection, use during as the preparation compound formulation.
Under aseptic condition, various compositions are combined, make compound formulation, be filled in the packing bottle of 100 milliliters, 250 milliliters or 500 milliliters.
Embodiment
The compound formulation example:
The composition of compound formulation.To have the Bacillus subtilis LY-35 and the E.Coli of representative configuration, cultivation, biochemical characteristic, the phage of Salmonella D enteriditis, Staphylococcus aureus, StreptococcusPyogenes, Proteus mirabili, Proteus Vulgaris, Pseudomonas aeruginosa, Klebsillapneumoniae is a basic ingredient, four kinds of compound formulations have been prepared, for ease of using and transportation, compound formulation is a concentrate formulation.
First kind of preparation contains
1, the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2, the phage titer of one milliliter of compound formulation E.Coli, Salmonella D, enteriditi, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, Klebsilla pneumoniae is 10
6(ten times of serial dilution methods).
3, enzyme suppresses stablizer: the EDTA of amount of formulation 0.5% (ethylenediamine tetraacetic acid (EDTA)).
Second kind of preparation contains
1, the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2, one milliliter of compound formulation E.Coli, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, the phage titer of Klebsilla pneumoniae are 10
6(ten times of serial dilution methods).
3, antibiotic stablizer: the oxine vitriol of amount of formulation 1%.
The third preparation contains
1, the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2, one milliliter of compound formulation E.Coli, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgari s, Pseudomonasaeruginosa, the phage titer of Klebsilla pneumoniae are 10
6(ten times of serial dilution methods).
3, antibiotic stablizer and enzyme suppress stabilizing agent dosage: the oxine vitriol of amount of formulation 1% and 0.5% EDTA (ethylenediamine tetraacetic acid (EDTA)).
The 4th kind of preparation contains
1, the viable count of Bacillus subtilis LY-35 is 1 * 10 in one milliliter of compound formulation
9
2, one milliliter of compound formulation E.Coli, Salmonella D enteriditis, Staphylococcus aureus, Streptococcus Pyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonasaeruginosa, the phage titer of Klebsilla pneurmoniae are 10
6(ten times of serial dilution methods).
3, no stablizer and enzyme inhibitors
The preparation of preparation pours in the sterilization bottle under aseptic condition and capping.Four kinds of preparations have been carried out comprehensive detection by following characteristic.
1, Bacillus subtilis LY-35 is to the special antagonism of conditioned pathogen.
2, Bacillus subtilis LY-35 is to the susceptibility of antibiotic preparation.
3, E.Coli, Salmonella D enteriditis, Staphylococcus aureus, StreptococcusPyogenes, Proteus mirabilis, Proteus Vulgaris, Pseudomonas aeruginosa, the Klebsillapneumoniae phage is to detecting the lytic activity of bacterium.
4, utilize white mouse to detect security.
5, deposit the change in concentration of the effective constituent of compound formulation in the process.
Detect the special antagonism of preparation to various pathogenic bacterium
Adopt delay antagonism method to test.With transfering loop vial is rule along the culture dish diameter, be inoculated in No. 2 substratum of Gao Shi (semi-synthetic cultivation), constant temperature culture is 24 hours under 37 ℃ of conditions, cultivates 24 hours under 22 ℃ of conditions then, at last perpendicular to culture streak inoculation pathogenic bacterium (0.5 * 10 again
9The bacteria suspension of 24 hours cultures of/milliliter), through after 18-24 hour constant temperature culture of 37 ℃, detect bacterium and do not have the contrast culture ware of Bacillus subtilis LY-35 with reference to the only inoculation of cultivating simultaneously, statistics detects the growing state of bacterium.
Table four: the antagonism (mm) of Bacillus subtilis LY-35 in four kinds of different preparations
| Type of preparation | 1 | 2 | 3 | 4 | |
| Suppress to detect the growth scope of bacterium | E.Coli | 25±2 | 24±2 | 26±2 | 25±2 |
| Salmonella D enteriditis | 20±2 | 2l±2 | 20±2 | 20±2 | |
| Staphylococcus aureus | 28±2 | 27±2 | 28±2 | 27±2 | |
| Streptococcus Pyogenes | 22±2 | 21±2 | 22±2 | 24±2 | |
| Proteus mirabilis | 20±2 | 22±2 | 21±2 | 20±2 | |
| Proteus Vulgaris | 20±2 | 21±2 | 20±2 | 19±2 | |
| Pseudomonas aeruginosa | 10±1 | 12±2 | 12±1 | 11±1 | |
| Klebsiella Pneumoniae | 18±2 | 17±2 | l 9±2 | 1 7±2 | |
Detect preparation to antibiotic susceptibility
Utilization is soaked with antibiotic normal disc and detects preparation to antibiotic susceptibility.Method is as follows: contain Bacillus subtilis LY-35 microorganism cells l * 10 from what be prepared into 0.9% sodium chloride solution
9Isolate bacterial classification in the compound formulation of/ml, make bacteria suspension behind the cultivation diel.Get bacteria suspension l milliliter and splash in the meat peptone agar culture dish, be evenly coated on the agar surface, the dropper sucking-off of unnecessary bacteria suspension will be soaked with antibiotic disk filter paper with tweezers and be put on the agar surface.Each culture dish is put five.The thermostat container of culture dish being put into (37 ± 1) ℃ is cultivated (18-24) hour.Calculate disk scraps of paper scope of restraining fungi on every side then, comprise the diameter of the scraps of paper itself.
Table five: Bacillus subtilis LY-35 is to antibiotic susceptibility in four kinds of different preparations
| Type of preparation | Antibiotic susceptibility (disk detection) is suppressed scope mm | |||
| Polymyxin | Rifomycin | Penicillin | Streptomycin sulphate | |
| 1 | 10 | 0 | 0 | l0±2 |
| 2 | 10 | 0 | 0 | l0±2 |
| 3 | 10 | 0 | 0 | 10±2 |
| 4 | 10 | 0 | 0 | 10±2 |
Detect the lytic activity of preparation pnagus medius
The lytic activity of check compound formulation pnagus medius composition adopts ten times of serial dilution methods.Bacillussubtilis LY-35 is removed by filter, with preparation by ten times of serial dilutions in broth culture, more a certain amount of standard conditions cause a disease are detected bacterium and splash into, observe the clarifying maximum dilution of meat soup and tire and can be used as detected result.
Table six: the preparation pnagus medius is to the lytic activity of conditioned pathogen in four kinds of different preparations
| Type of preparation | 1 | 2 | 3 | 4 | |
| Special antibiotic work to conditioned pathogen | E.Coli | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 |
| Salmonella D enteriditis | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
| Staphylococcus aureus | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
| Streptococcus Pyogenes | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
| Proteus mirabilis | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
| Proteus Vulgaris | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
| Pseudomonas aeruginosa | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
| Klebsiella Pneumoniae | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | 10 6-10 7 | |
Detect the security of preparation
The security of check compound formulation.Get in the bottle 0.5 milliliter in preparation in the oral cavity is injected into the white mouse body, use the white mouse of ten above weight, detect each preparation as the 15-16 gram.If white mouse is all survivals in five days observation period, and none illness symptom occurs, then preparation thinks safe and harmless.
Table seven: the body weight change of white mouse after metering of per os use compound formulation
| Type of preparation | Experiment white mouse quantity | White mouse survival quantity | White mouse mean body weight (gram) | ||
| Before taking | After taking | ||||
| Diel | Five round the clock | ||||
| 1 | 10 | 10 | 15.10 | 15.30 | 15.52 |
| 2 | 10 | 10 | 15.42 | 15.45 | 16.08 |
| 3 | 10 | 10 | 15.80 | 15.80 | 16.42 |
| 4 | 10 | 10 | 15.60 | 15.65 | 17.00 |
Experiment shows that all white mouse survives, and disease symptom does not appear in weight increase.Detect the variation of effective constituent concentration in preparation (liquid) storage
Table eight: the variation of the concentration of Bacillus subtilis LY-35 in four kinds of different preparations
| Storage-life (moon) | The bacterial cell concentration C FU/ milliliter of different preparations | |||
| 1 | 2 | 3 | 4 | |
| 0 (starting point concentration) | 1×10 8 | 1×10 8 | 1×10 8 | 1×10 8 |
| After 3 months | 1×10 8 | 5×10 7 | 5×10 7 | 1×10 7 |
| After 6 months | 1×10 7 | 1×10 6 | 1×10 6 | 5×10 5 |
| After 9 months | 1×10 6 | 1×10 5 | 1×10 5 | 5×10 4 |
| After 12 months | 1×10 5 | 5×10 4 | 5×10 4 | 1×10 4 |
Table nine: four kinds of different preparations are to the variation (ten times of serial dilutions) of conditioned pathogen lytic activity
| Storage-life (moon) | Tire (mean value) of the lytic activity of phage composition | |||
| 1 | 2 | 3 | 4 | |
| 0 (starting point concentration) | 10 -8 | 10 -8 | 10 -8 | 10 -8 |
| After 3 months | 10 -7 | 10 -5 | 10 -7 | 10 -7 |
| After 6 months | 10 -6 | 10 -3 | 10 -6 | 10 -5 |
| After 9 months | 10 -6 | 10 -3 | 10 -6 | 10 -5 |
| After 12 months | 10 -5 | 10 -2 | 10 -5 | 10 -5 |
From table eight and table nine, as can be seen, contain enzyme and suppress the preparation of stablizer 0.5%EDTA and contain oxine vitriol storage effect the best that enzyme suppresses stablizer 0.5%EDTA+ antiseptic-germicide 1%, i.e. first kind and the third preparation.
Application example
Application example one: use compound formulation treatment garget, endometritis.
In use, measuring the average daily optimum amount for the treatment of garget is that a kg body weight is to Bacillussubtilis LY-35 viable count 1 * 10
9, the lytic activity of phage is 10
6During the treatment bovine endometritis, use syringe to inject uterine cavity.During the treatment mastitis, utilize conduit to be injected in the newborn pond.When using simultaneously with microbiotic, medical expense has descended 20%, and laboring fee has descended 50%, for the validity of ox Catarrhal and suppuration Catarrhal mastitis between 55%-95%, than the high 13.7-25.0% of validity that uses other antibiotic preparations in the newborn pond.
Application example two: use compound formulation treatment cub, measured the action effect of liquid preparation to piglet.
The average daily optimum amount of measuring piglet is that a kg body weight is to Bacillus subtilis LY-35 viable count (0.3-0.5) * 10
9, the lytic activity of phage is 10
6In 10-30 use every day in day, the best results of preparation.The weight average of piglet increases 15-30%, is not increasing under the situation that feed and breeding expenses use, and the cub mortality ratio that causes because of gastrointestinal tract disease and tuberculosis reduces, and in addition, uses new preparation can shorten the adaptive phase of piglet to new feedstuff and new raising condition.In addition, adopt simulation experiment method to detect the effect of preparation.With 1.5-2 the calf infection Escherichia Coli and the ProteusVulgaris pathogenic bacterium in age in week, the effect of preparation is fine, has very strong inhibition pathogenic bacterium growth, recover gi tract germ group's ability, promptly showing as the cub that suffers from dysentery significantly reduces, compare with control group, every day, body weight increased more than 50% more.
Claims (1)
1, a kind of subtilis, name is called Bacillus subtilis LY-35, and its biochemical characteristic is: strain fermentation glucose, sucrose, maltose, N.F,USP MANNITOL, form acid, aerogenesis does not reduce lactose; Do not form indoles, hydrogen sulfide; The V-P reaction is positive, make catalase, proteolytic enzyme, gelatinase, Ntn hydrolase, do not form ovum esterase, lipase, urase, do not form hemolysin and Tryptase, the anti-benzylpenicillin of bacterial strain, carboxy benzyl penicillin, penbritin, polymyxin, peace Qu Nan, but to woods enzyme element, enzyme element, tsiklomitsin are insensitive through the ages; It is in China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation, and its deposit number is: CGMCC NO.1222.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100454433A CN100352915C (en) | 2004-11-30 | 2005-11-28 | Bacillus subtilis, composite preparation, and method for preparing the composite preparation |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410036542 CN1632103A (en) | 2004-11-30 | 2004-11-30 | Bacillus subtilis, its combination preparation and method for preparing combination preparation |
| CN200410036542.0 | 2004-11-30 | ||
| CNB2005100454433A CN100352915C (en) | 2004-11-30 | 2005-11-28 | Bacillus subtilis, composite preparation, and method for preparing the composite preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1796542A CN1796542A (en) | 2006-07-05 |
| CN100352915C true CN100352915C (en) | 2007-12-05 |
Family
ID=36817862
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100454433A Expired - Fee Related CN100352915C (en) | 2004-11-30 | 2005-11-28 | Bacillus subtilis, composite preparation, and method for preparing the composite preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100352915C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102191189B (en) * | 2010-03-03 | 2013-03-20 | 林秀霞 | Novel probiotic strain and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2118364C1 (en) * | 1997-07-23 | 1998-08-27 | Волгоградский научно-исследовательский противочумный институт | Strain bacillus subtilis tpaxc showing resistance to tetracycline, rifampicin, ampicillin, chloramphenicol, streptomycin and exhibiting antibacterial activity with respect to pathogenic microorganism species |
| CN1248622A (en) * | 1999-09-27 | 2000-03-29 | 李开义 | Compound microecological preparation |
-
2005
- 2005-11-28 CN CNB2005100454433A patent/CN100352915C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2118364C1 (en) * | 1997-07-23 | 1998-08-27 | Волгоградский научно-исследовательский противочумный институт | Strain bacillus subtilis tpaxc showing resistance to tetracycline, rifampicin, ampicillin, chloramphenicol, streptomycin and exhibiting antibacterial activity with respect to pathogenic microorganism species |
| CN1248622A (en) * | 1999-09-27 | 2000-03-29 | 李开义 | Compound microecological preparation |
Non-Patent Citations (1)
| Title |
|---|
| 微生物制剂的作用机理、功能及在动物生长中的应用 王芬，宁志力，范宪生.中国动物保健 2004 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1796542A (en) | 2006-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100494093C (en) | Nourishing water conditioning agent for aquiculture | |
| CN105062933A (en) | Lactobacillus reuteri and application thereof | |
| CN107047934A (en) | Using bacillus subtilis strain to strengthen the method for animal health | |
| CN101629157A (en) | Compound microecologics for purifying water quality | |
| CN104855684B (en) | A kind of antibacterial Chinese medicine microbial fermentation preparation and its preparation method and application | |
| CN109161509A (en) | One plant of bacterial strain that can prevent and treat cattle and sheep diarrhoeal diseases | |
| CN106754551A (en) | A kind of bacterium amount lactobacillus preparation high and preparation method and application | |
| CN103005159A (en) | Preparation method of ginkgo leaf biological feed additive | |
| Al-Bashan | In vitro assessment of the antimicrobial activity and biochemical properties of camel's urine against some human pathogenic microbes | |
| CN105062921A (en) | Lactobacillus salivarius for efficiently inhibiting avian pathogenic salmonella and application of lactobacillus salivarius | |
| CN106867933A (en) | The probiotics of purification of water quality and preparation and application in being cultivated to Environment of Litopenaeus vannamei Low | |
| CN100584209C (en) | Feed level microbe additive and its preparation and application | |
| CN109549024A (en) | A kind of fish feed additive and preparation method thereof | |
| CN109321505A (en) | A kind of complex microorganism preparations adjusting aquatic livestock enteron aisle | |
| CN114134083B (en) | Bacillus bailii and application thereof | |
| CN109549025A (en) | One seed shrimp feed addictive and preparation method thereof | |
| KR20080050506A (en) | Additive for animal feed | |
| CN105858909A (en) | Microbial herbal composite preparation for aquiculture and preparation method thereof | |
| CN110982753A (en) | Bacillus coagulans MES847, microbial inoculum, chicken feed, preparation method and application | |
| CN103667140B (en) | A kind of compound synergic method of enterococcus faecalis and application thereof | |
| CN1057563C (en) | Bacterial stain of bacillus subtilis and application thereof | |
| CN107988091A (en) | A kind of new livestock and poultry colony house environmental improvement agent and its preparation method and application | |
| CN110093288B (en) | Quick-fermentation composite probiotic regulator for improving water quality of aquaculture farm | |
| CN112574924B (en) | Bacillus subtilis strain, microecological preparation and application thereof | |
| CN101891307B (en) | Marine culture biological cleanser and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071205 Termination date: 20151128 |